12. Makkeyah S, Manzour A, Tantawy A, Mohamed A, Ebeid F, El-Sherif N, Abd El-Ghany S, Shawiesh M, Ali H, Sayed S, Ragab I. Treatment outcomes for childhood acute lymphoblastic leukemia in low-middle income country before minimal residual disease risk stratification. Cancer Epidemiology. 2021 Dec 1;75:102040.
13. Ebeid FSE, Ragab IA, Elsherif NHK, Makkeyah S, Mostafa S, Eltonbary K, Matbouly S, Mostafa A, Goma H, Agwa SH, Hafez HM, Girgis S, El Gendy YG, El-Sayed MH. COVID-19 in Children With Cancer: A Single Low-Middle Income Center Experience. J Pediatr Hematol Oncol. 2021 Nov 1;43(8):e1077-e1081. doi: 10.1097/MPH.0000000000002025. PMID: 33290293.
14. Elalfy Mohsen S, Kenny Mahmoud A, Saed Fatima Z.A, Ebeid Fatma S.E.
Alloimmunization in Egyptian children with sickle cell disease
EJH 2021; 46 (1): 41-47.
15. El-Baraky IA, Abbassi MM, Ebeid FS, Hassany M, Sabry NA, El-Sayed MH. Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101747. doi: 10.1016/j.clinre.2021.101747. Epub 2021 Jun 26. PMID: 34186262.
16. Elalfy MS, Ibrahim AS, Ibrahim GS, Hussein HMAG, Mohammed HGE, Ebeid FSE. Hidden brain iron content in sickle cell disease: impact on neurocognitive functions. Eur J Pediatr. 2021 Aug;180(8):2677-2686. doi: 10.1007/s00431-021-04189-7. Epub 2021 Jul 8. PMID: 34236515.
17. ElAlfy MS, Tantawy AAG, Eldin BEMB, Mekawy MA, Mohammad YAE, Ebeid FSE. Epistaxis in a Pediatric Outpatient Clinic: Could It be an Alarming Sign?. Int Arch Otorhinolaryngol. 2021;26(2):e183-e190. Published 2021 Jun 3. doi:10.1055/s-0041-1726040. ISSN 1809-9777.
18. Agwa SHA, Kamel MM, Elghazaly H, Abd Elsamee AM, Hafez H, Girgis SA, Ezz Elarab H, Ebeid FSE, Sayed SM, Sherif L, Matboli M. Association between Interferon-Lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 Variant Polymorphisms with the Course and Outcome of SARS-CoV-2 Patients. Genes (Basel). 2021 May 28;12(6):830. doi: 10.3390/genes12060830. PMID: 34071309; PMCID: PMC8230293.
19. Mostafa A, Kandil S, El-Sayed MH, Girgis S, Hafez H, Yosef M, Saber S, Ezzelarab H, Ramadan M, Algohary E, Fahmy G, Afifi I, Hassan F, Elsayed S, Reda A, Fattuh D, Mahmoud A, Mansour A, Sabry M, Habeb P, Ebeid FS, Elanwar A, Saleh A, Mansour O, Omar A, El-Meteini M. SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study. Int J Infect Dis. 2021 Mar;104:534-542. doi: 10.1016/j.ijid.2021.01.037. Epub 2021 Jan 20. PMID: 33484863; PMCID: PMC7817419.
20. El-Sayed MH, Said ZNA, Abo-Elmagd EK, Ebeid FSE, Salama II. High Risk of HBV Infection Among Vaccinated Polytransfused Children With Malignancy. J Pediatr Hematol Oncol. 2021 Jan;43(1):e45-e50. doi: 10.1097/MPH.0000000000001887. PMID: 32769568.
21. Mostafa A, Kandil S, El-Sayed MH, Girgis S, Hafez H, Yosef M, Saber S, Ezzelarab H, Ramadan M, Afifi I, Hassan F, Elsayed S, Reda A, Fattuh D, Mahmoud A, Mansour A, Sabry M, Habeb P, Ebeid FS, Saleh A, Mansour O, Omar A, El-Meteini M. Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers. Int J Epidemiol. 2021 Mar 3;50(1):50-61. doi: 10.1093/ije/dyaa173. PMID: 33094320; PMCID: PMC7665557.
22. Omar T, Abd-Elhalim E, Eledel R, Soliman M, Ebeid FS, Elshafey O, Abou-Elela, D. Genetic Polymorphisms of HBS1L-MYB (rs4895441 and rs9376090) in Egyptian Patients with Hemoglobinopathy. Open Journal of Blood Diseases 2020; 10: 89-100. doi: 10.4236/ojbd.2020.104011.
23. Mostafa A, Ebeid FSE, Khaled B, Ahmed RHM, El-Sayed MH. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies. Trop Med Int Health. 2020 Jul;25(7):850-860. doi: 10.1111/tmi.13404. Epub 2020 May 29. PMID: 32306545.
24. Ebeid FSE. COVID-19 effect on clinical research: Single-site risk management experience. Perspect Clin Res. 2020 Jul-Sep;11(3):106-110. doi: 10.4103/picr.PICR_119_20. Epub 2020 Jul 6. PMID: 33033698; PMCID: PMC7513789.
25. Al-Nahari MM, Abbassi MM, Ebeid FS, Hassany M, El-Sayed MH, Farid SF. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. Antivir Ther. 2020;25(2):101-110. doi: 10.3851/IMP3357. PMID: 32367815.
26. Tantawy AAG, Tadros MAR, Adly AAM, Ismail EAR, Ibrahim FA, Salah Eldin NM, Hussein MM, Alfeky MA, Ibrahim SM, Hashem MA, Ebeid FSE. Endothelin-1 gene polymorphism (G8002A) and endothelial monocyte-activating polypeptide II: Role in vascular dysfunction in pediatric patients with β-thalassemia major. Cytokine. 2022 Oct 21;161:156048. doi: 10.1016/j.cyto.2022.156048. Epub ahead of print. PMID: 36279697.
27. Raief Mosaad BM, Ibrahim AS, Mansour MG, ElAlfy MS, Ebeid FSE, Abdeldayem EH. The role of MRI-R2* in the detection of subclinical pancreatic iron loading among transfusion-dependent sickle cell disease patients and correlation with hepatic and cardiac iron loading. Insights Imaging. 2022 Sep 4;13(1):140. doi: 10.1186/s13244-022-01280-x. PubMed PMID: 36057708.
28. Ebeid FSE, Khan NIH. The Adverse Impact of Thalassemia Major on Adolescents' Oral Health-related Quality of Life. J Pediatr Hematol Oncol. 2020 Jul;42(5):e345-e351. doi: 10.1097/MPH.0000000000001729. PMID: 32011564.
29. Elalfy MS, Ebeid FSE, El Gendy YG, Zaki MM, Kalifa ASA. Body Composition in Egyptian Children With Transfusion-dependent Thalassemia: The Impact of Nutrition and Metabolic Profile. J Pediatr Hematol Oncol. 2020 Jul;42(5):e334-e339. doi: 10.1097/MPH.0000000000001712. PMID: 31929387.
30. Tantawy AA, Ragab IA, Ismail EA, Ebeid FSE, Al-Bshkar RM. Reticulocyte Hemoglobin Content (Ret He): A Simple Tool for Evaluation of Iron Status in Childhood Cancer. J Pediatr Hematol Oncol. 2020 Apr;42(3):e147-e151. doi: 10.1097/MPH.0000000000001700. PMID: 31851071.
31. Andrawes NG, Ismail EA, Roshdy MM, Ebeid FSE, Eissa DS, Ibrahim AM. Angiopoietin-2 as a Marker of Retinopathy in Children and Adolescents With Sickle Cell Disease: Relation to Subclinical Atherosclerosis. J Pediatr Hematol Oncol. 2019 Jul;41(5):361-370. doi: 10.1097/MPH.0000000000001486. PMID: 30994508.
32. Tantawy AA, Adly AA, Ebeid FSE, Ismail EA, Hussein MM, Shaarawy RM, Kamel RA. Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests. Pediatr Pulmonol. 2019 May;54(5):610-619. doi: 10.1002/ppul.24257. Epub 2019 Jan 22. PMID: 30672154.
33. ElAlfy MS, Ebeid FSE, Kamal TM, Eissa DS, Ismail EAR, Mohamed SH. Angiotensinogen M235T Gene Polymorphism is a Genetic Determinant of Cerebrovascular and Cardiopulmonary Morbidity in Adolescents with Sickle Cell Disease. J Stroke Cerebrovasc Dis. 2019 Feb;28(2):441-449. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.019. Epub 2018 Nov 5. PMID: 30409744.
34. Ibrahim WE, Ebeid FSE, Mohamed RM. The Role of Pre-B-cell Colony- Enhancing Factor in Egyptian Children with Hemophagocytic Lymphohistiocytosis. The Egyptian Journal of Haematology 2018; 43(1):1-4
35. Ebeid FSE, Baioumi AY, Elzaree F, Ibrahim FA. Obesity in Egyptian Children: Influence of Oxidant-Antioxidant Status on Lipid and Glucose Homeostasis Journal of Steroids & Hormonal Science Jul 2018; 9 (2):1-7
36. Elalfy MS, Ebeid FSE, Elgamry IR, Fawzy GM, Elsedfy HH, Hamza MT. Hazardous Influence of Hydroxyurea on Spermatogenesis in Thalassemia Intermedia Patients: An Egyptian Cohort Study. Journal of Drug Metabolism and Toxicology Jun 2018; 9:2:1-5
37. ElAlfy MS, Adly AAM, Ebeid FSE, Eissa DS, Ismail EAR, Mohammed YH, Ahmed ME, Saad AS. Immunological role of CD4+CD28null T lymphocytes, natural killer cells, and interferon-gamma in pediatric patients with sickle cell disease: relation to disease severity and response to therapy. Immunol Res. 2018 Aug;66(4):480-490. doi: 10.1007/s12026-018-9010-y. PMID: 29926339.
38. ElAlfy MS, Khalil Elsherif NH, Ebeid FSE, Ismail EAR, Ahmed KA, Darwish YW, Ibrahim AS, Elghamry IRF, Shokrey NA, Alajeil DN. Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy. Eur J Radiol. 2018 Jun;103:65-70. doi: 10.1016/j.ejrad.2018.04.007. Epub 2018 Apr 9. PMID: 29803388.
39. Elalfy MS, Ebeid FSE, Elagouza IA, Ibrahim FA, Hassan NBM, Botros BA. Negative Impact of Prolonged Antibiotics or Persistent Diarrhea on Vitamin K1 Levels in 2-24 Weeks aged Egyptian Infants. Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018010. doi: 10.4084/MJHID.2018.010. PMID: 29326806; PMCID: PMC5760067.
40. El-Din LB, Ebeid FSE, Toaima NN, Ibrahim WW. Hypoparathyroidism in children with Beta thalassemia major and its relation to Iron Chelation Therapy. The Egyptian Journal of Haematology Apr Jun 2018; (43) 2: 63-68.
41. Ebeid FSE, Khalifa AS, El-Kinawy NS, Helmy SY. Cytokines and immunoglobulin derangement in Egyptian children with primary immune thrombocytopenic purpura. The Egyptian Journal of Haematology Jan Mar 2018; (43) 1: 1-4
42. Mokhtar GM, El Alfy MS, Ebeid FSE, El Sawi MA, Fayek MH, Adly AAM and Asama Zaki. Hemochromatosis C282Y gene mutation as a potential susceptibility factor for iron-overload in Egyptian beta-thalassemia Patients. Egyptian Journal of Medical Human Genetics 2018; (19): 103–106.
43. Abaza HM, Alfeky MAA, Eissa DS, Abdel Fattah MF, Annaka LM, Ebeid FS. Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker. J Pediatr Hematol Oncol. 2018 Apr;40(3):200-207. doi: 10.1097/MPH.0000000000001008. PMID: 29200164.
44. Tantawy AAG, Ebeid FSE, Adly AAM, El-Ghoroury E, Mostafa M. Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia. J Genet. 2017 Dec;96(6):905-910. doi: 10.1007/s12041-017-0853-0. PMID: 29321348.
45. Ebeid FSE, Skinner R. Risk and prognostic factors for invasive fungal diseases in paediatric patients with malignancy. The Egyptian Journal of Haematology 2015, 40:55–59.
46. Adly AAM, Ismail EA, Tawfik LM, Ebeid FSE, Hassan AAS. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 2015 Dec;76(2):156-162. doi: 10.1016/j.cyto.2015.06.006. Epub 2015 Jul 2. PMID: 26142824.
47. Tantawy AA, Barakat MM, Adly AA, Ebeid FS, Shamaa MF, Yassin M. One-Year Prospective Study of Community Acquired Influenza and Parainfluenza Viral Infections in Hospitalized Egyptian Children with Malignancy: Single Center Experience. Pediatr Hematol Oncol. 2015;32(5):304-14. doi: 10.3109/08880018.2015.1013230. Epub 2015 Apr 14. PMID: 25871509.
48. Adly AA, Ebeid FS. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt. J Pediatr Hematol Oncol. 2015 May;37(4):281-4. doi: 10.1097/MPH.0000000000000327. PMID: 25811748.
49. Tantawy AA, El Bablawy N, Adly AA, Ebeid FS. Early Predictors of Renal Dysfunction in Egyptian Patients with β-Thalassemia Major and Intermedia. Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014057. doi: 10.4084/MJHID.2014.057. PMID: 25237470; PMCID: PMC4165495.
50. Khalifa AS, Bishry Z, Tantawy AA, Ghanem MH, Effat SM, El Shahawy H, Ebeid FS. Psychiatric morbidity in Egyptian children with acute lymphoblastic leukemia and their care providers. Hematol Oncol Stem Cell Ther. 2014 Jun;7(2):76-84. doi: 10.1016/j.hemonc.2014.01.002. Epub 2014 Mar 11. PMID: 24631570.
51. Tantawy AA, El Sherif NH, Ebeid FS, El-Desouky ED. Survival analysis after diagnosis with malignancy of Egyptian adolescent patients: a single-center experience. J Pediatr Hematol Oncol. 2014 Aug;36(6):e346-52. doi: 10.1097/MPH.0000000000000114. PMID: 24517961.
52. Tantawy AA, Ebeid FS, Mahmoud MA, Shepl OE. Spinal cord compression in childhood pediatric malignancies: multicenter egyptian study. J Pediatr Hematol Oncol. 2013 Apr;35(3):232-6. doi: 10.1097/MPH.0b013e318270b210. PMID: 23511492.
53. Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. Hematol Oncol Stem Cell Ther. 2010;3(4):174-8. doi: 10.5144/1658-3876.2010.174. PMID: 21150236.
54. Abdel-Aziz DH, Sabry NA, El-Sayed MH, El-Gazayerly ON (2011): Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study. J Pharm Pract; 24(2):203-10.
55. El-Sayed MH, Nasr E, Zekri A, El-Beblawy N, Abdel Aziz AO, Zalata KR, Delgado-Borrego A, El-Haddad A (2011): Factors Associated with Fibrosis Among HCV Infected Children and Adolescents Receiving Cancer Chemotherapy. Hepatology; 54, S1:715.
56. Mohammed Saif M, Farid SF, Khaleel SA, Sabry NA, El-Sayed MH (2012): Hepato-protective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia. Pediatr Hematol Oncol; 29(7):627-32.
57. Breban R, Doss W, Esmat G, El-Sayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK. (2013): (short report) Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat; 20(4):294-6.
58. Progress toward prevention and control of hepatitis C Virus infection -Egypt, 2001-2012 (2012): Morbidity and Mortality Weekly Report (MMWR). July 27, 2012 / 61(29);545-549.
59. Al-Ofairi BA, El-Sayed MH, Al-Ghanem HA, Barakat AB, Shehata IH (2013): Cellular adaptive immune status in Egyptian thalassemic patients with chronic hepatitis C virus infection. J Clin Exp Hepatol; 3 (1), Suppl:S62.
60. El-Sayed MH, Ibrahim D, Omar W, Zalata K, El-Haddad A (2013): Role of liver biopsy in assessment of liver dysfunction in HCV-infected children following hematopoietic bone marrow transplantation. J Hepatol; 58 (S1):P1388-S558.
61. Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK. Quantifying current hepatitis C virus incidence in Egypt - Response to letter by Miller and Abu-Raddad. J Viral Hepat. 2013 Sep;20(9):668. doi: 10.1111/jvh.12092.
62. Said ZN, El-Sayed MH, Salama II, Aboel-Magd EK, Mahmoud MH, El-Setouhy M, Mouftah F, Azzab MB, Goubran H, Bassili A, Esmat G (2013): Occult hepatitis B infection among Egyptian blood donors. World J Hepatol; 27;5(2):64-73.
63. El-Sayed MH, Matar RM, Abdel-Gawad AN, Abdel-Aziz MM, Esmat GE, Mokhtar GM (2013): Hepcidin and Iron Overload in HCV-infected Children with Acute Leukemia. Hepatology; 58 (S1): P1226-806A.
64. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, et al. (2014): Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat.; 21 Suppl 1:60-89.
65. Razavi H, Waked I, Sarrazin C, Myers RP, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014). J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.1:34-59.
66. Bruggmann P, Berg T, Øvrehus AL, et al. (2014): Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat;21 Suppl 1:5-33.
67. Waked I, Doss W, El-Sayed MH, Estes C, Razavi H, Shiha G, Yosry A, Esmat G (2014): The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol;15(2):45-52.
68. El-Sayed MH, Toaima D, Marzouk FA, Mohsen A, El-Sharkawy A, Esmat GE, El-Haddad A (2014): APRI, FIB-4 and Fibroscan in Prediction of Significant Fibrosis in Adolescent Cancer Survivors in a Resource Limited Country. Hepatology; 60 (S1): P681-530 A.
69. Metwally A, Mohsen A, Saleh R, Foaud W, Ibrahim N, Rabaah T, El-Sayed M (2014): Prioritizing High-Risk Practices and Exploring New Emerging Ones Associated With Hepatitis C Virus Infection in Egypt. Iran J Public Health;43(10):1385-94.
70. Al-Tawil MM, Shoeeb AS, Abbas A, El-Tawil A, El-Sayed MH (2015): Lipid profile and hepatic steatosis in hepatitis C infected Egyptian survivors of childhood cancer. Pediatr Hematol Oncol;32(1):70-7.
71. El-Sayed MH, Razavi H. Global estimate of HCV infection in the pediatric and adolescent population (2015). P1263. J Hepatol; 62:S831–S832.
72. Hamed AA, Darwish YW, El-Sayed MH (2015): ADAMTS13 Levels in Young Patients With β-Thalassemia Major: Relation to Hepatitis C Virus Infection, Liver Cirrhosis, and Iron Overload. Clin Appl Thromb Hemost;21(6):527-32.
73. Salama II, Sami SM, Said ZNA, El-Sayed MH, El Etreby LA, Rabah TM, Elmosalami DM, Abdel Hamid AT, Salama SI, Abdel-Mohsen AM, Emam HM, Elserougy SM, Hassanain AI, Abd Alhalim NF, Shaaban FA, Hemeda SA, Ibrahim NA, Metwally AM (2015). Effectiveness of hepatitis B virus vaccination program in Egypt: Multicenter national project. World J Hepatol;7(22):2418.
74. Abdelaziz DH, Elhosseiny NM, Khaleel SA, Sabry NA, Attia AS, El-Sayed MH (2016). Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes with Toxicities of Methotrexate and 6-Mercaptopurine in Children with Acute Lymphoblastic Leukemia. Pediatr Blood Cancer;63(9):1539-45.
75. Al-Ghobashy MA, Hassan SA, Abdelaziz DH, Elhosseiny NM, Sabry NA, Attia AS, El-Sayed MH (2016). Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism. J Chromatogr B Analyt Technol Biomed Life Sci;1038:88-94.
76. Eletreby R, Elakel W, Said M, Elkassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G (2017). Real life Egyptian experience of efficacy and safety of Simeprevir\ Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int;37(4):534-541.
77. The Polaris Observatory Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastro & Hepatol;2(3):161-176.
78. El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, Kabil K, Hassany M, Shawky A, Yosry A, Shaker MK, ElShazly Y, Waked I, Esmat G, Doss W (2017). National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat ;24(4):262-267.
79. Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP (2017). The Challenge of Treating Children with Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr;64(6):851-854.
80. Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G (2017). Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res;37(8):348-353.
81. Elsharkawy A, Raziky ME, Akel WE, Saeed KE, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, Shazly YE, Esmat G, Waked I (2017). Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience. J Hepatol; S0168-8278(17)32478-9.
82. El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, RizK A, Maher M, El Sheemy RY, Fouad YM, Attia D (2018). The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther;47(6);838-844.
83. Salama II, Sami SM, Said ZN, Salama SI, Rabah TM, Abdel-Latif GA, Elmosalami DM, Saleh RM, Abdel Mohsin AM, Metwally AM, Hassanin AI, Emam HM, Hemida SA, Elserougy SM, Shaaban FA, Fouad WA, Mohsen A, El-Sayed MH (2018). Early and long term anamnestic response to HBV booster dose among fully vaccinated Egyptian children during infancy. Vaccine;5;36(15):2005-2011.
84. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study (2018). Lancet Gastroenterol Hepatol;3(6):383-403.
85. El-Sayed MH, Ebeid FSES, Zekri AR, Massetto B, Kersey K, Osinusi A, Zhang F, Brainard D, Elsayed W, El-Haddad A (2018). Ledipasvir/Sofosbuvir for 12 weeks is safe and effective in adolescents with chronic hepatitis C virus infection and hematological malignancies undergoing chemotherapy. J Hepatol; 68, Suppl 1:S515.
86. Attia D, El Saeed K, Elakel W, El Baz T, Omar A, Yosry A, Elsayed MH, Said M, El Raziky M, Anees M, Doss W, El Shazly Y, Wedemeyer H, Esmat G (2018). The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther;47(9):1296-1305.
87. Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M (2018). The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Semin Liver Dis;38(3):181-192.
88. Esmat G, El-Sayed MH, Hassany M, Doss W, Waked I (2018); National Committee for the Control of Viral Hepatitis. One step closer to elimination of hepatitis C in Egypt. Lancet Gastroenterol Hepatol;(10):665.
89. Popping S, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J (2019). The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. J Virus Erad;1;5(1):60-66.
90. El-Sayed MH, Hassany M, El Sayed Ebeid FS, Zeidan A, Asem N (2019). Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents. J Hepatol;70 (S1): e221
91. El-Sayed MH, Elakel W, Elsharkawy A, Eletreby R, Elsaeed K, Elshazly Y, Elserafy M (2019). DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome. J Hepatol; 70 (S1): e221.
92. Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M (2019). Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol;4(6):466-476.
93. Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M (2019). Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol;4(6):477-487.
94. Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH (2019). Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis from Egypt. Value Health Reg Issues;19:51-58.
95. Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, Salama RM, El-Sayed MH, El Kassas M, Anees M, Shedeed M, Abdelsalam F, Ziada DH, El Shazly Y, El-Serafy M, Waked I, Esmat G, Doss W (2019). Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol;13(10):1009-1016.
96. Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G (2019). Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int;40(4):797-805.
97. Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, Estes C, Gamkrelidze I, Jerabek K, Ma S, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Razavi H, El Sayed MH (2020). Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol;5(4):374-392.
98. Abdel-Razek W, Hassany M, El-Sayed MH, El-Serafy M, Doss W, Esmat G, Waked I (2020). Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. Clin Liver Dis (Hoboken);14(6):203-206.
99. Mostafa A, Ebeid FSE, Khaled B, Ahmed RHM, El-Sayed MH (2020). Micro-elimination of Hepatitis C Through Testing of Egyptian Pregnant Women Presenting at Delivery: Implications for Screening Policies. Trop Med Int Health;25(7):850-860.
100. Al-Nahari MM, Abbassi MM, Ebeid FS, Hassany M, El-Sayed MH, Farid SF (2020). Pharmacokinetics of Daclatasvir in Egyptian Adolescents with genotype-4 HCV Infection. Antivir Ther;25(2):101-110.
101. Lazarus JV, Negro F, El-Sayed M, Colombo M (2020). A Letter of Solidarity During the COVID-19 Pandemic. Liver Int;40(11):2877-2878.
102. El-Sayed MH, Indolfi G (2020). Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Semin Liver Dis;40(3):213-224.
103. Cox AL, El-Sayed MH, Kao J-H, Lazarus JV, Lemoine M, Lok A, Zoulim F (2020). Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol;17(9):533-542.
104. El-Sayed MH, Said Z, Abo-Elmagd EK, Ebeid FSE, Salama II (2020). High Risk of HBV Infection among Vaccinated Polytransfused Children with Malignancy. J Pediatric Hematol/Oncol; 43(1):e45-e50.
105. El-Sayed MH, Thabet RA, Hamza MT, Hussein MS, El Saeed MM (2020). Liver disease in children and adolescents with type 1 diabetes mellitus: A link between glycemic control and hepatopathy. Diabetes Res Clin Pract; 170:108458.
106. Razavi H, Blach S, Razavi-Shearer D and Polaris Observatory Collaborators (2020). The case for simplifying and using absolute targets for viral hepatitis elimination goals. Viral Hepat;28(1):12-19.
107. Abdel Monem MS, Farid SF, Abbassi MM, Yosry I, Andraues NG, Hassany M, Selim YMM, El-Sayed MH (2021). The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: Randomised clinical trial. Int J Clin Pract;75(6):e14104.doi: 10.1111/ijcp.14104.
108. Cressey TR, Abbassi M, Lallemant M, Indolfi G, Al-Nahari M, Farid S, Easterbrook P, Penazzato M, El-Sayed MH (2021). Adequate Daclatasvir Exposures in Children 14-35 kg with Available Adult Formulations. CROI; Spotlight- J1:abst.444.
109. AbdAllah M, Alboraie M, Abdel-Razek W, Hassany M, Ammar I, Kamal E, Alalfy M, Okasha A, El Akel W, Shaaban E, Elbaz T, Hefny Z, Gomaa A, El-Bendary M, El-Serafy M, Esmat G, Doss W, El-Sayed MH (2021). Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver Int; 41(7):1494-1497. doi: 10.1111/liv.14913.
110. Naguib GG, Michael TG, Elshazly Y, Wahdan MM, Mostafa A, Ahmed OA, Dabbous H, Aly HIS, Shaker MK, Elbaz HS, El-Serafy M, Doss W, Abd-Elsalam S, El-Sayed MH (2021). The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. Virusdisease;32(3):582-588. doi: 10.1007/s13337-021-00712-4.
111. El-Baraky IA, Abbassi MM, Ebeid FS, Hassany M, Sabry NA, El-Sayed MH (2021). Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. Clin Res Hepatol Gastroenterol ;45(5):101747.
112. Naguib GG, Farid A, Hassan M, Elshafie A, Shazly YE, Shaker MK, Ezzat H, Safwat E, Ahmed OA, Dabbous H, Sherief AF, Hassany M, Elserafy M, Elsayed MH (2021). Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. Arab J Gastroenterol;22(4):285-291.
113. Cressey TR, Abbassi M, Lallemant M, Indolfi G, Al-Nahari M, Farid S, Easterbrook P, Penazzato M, El-Sayed MH (2021). Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations. Pediatr Infect Dis J;40(12):1081-1086.
114. El-Sayed MH, Feld JJ. Vaccination at the forefront of the fight against hepatitis B and C. Nat Rev Gastroenterol Hepatol. Dec 21.doi: 10.1038/s41575-021-00570-x.
115. Ebeid FSE, Mokhtar GM, Zaky EA, Abdelmageed RI, Elkamel NM, Ali HGA. Psychosocial and mental profile of children with sickle cell disease and their caregivers. Pediatr Hematol Oncol. 2024;41(1):15-29.
116. Ebeid FSE, Ali NH, Sallam SFA, Mostafa S, Gohar AMS, Tolba MW, Adly AA. Efficacy of Vitamin D Supplementation on Clinical Outcomes of Children with Sickle Cell Disease. Egyptian Journal of Haematology accepted 27 Jan 2024. [Epub ahead of print]
117. Ebeid FSE, Karm El-Din LA, El-Gamal HA, Sabra NMH, AboZayed A, Makkeyah SMM. The Clinical Significance of the Platelet Membrane Glycoproteins in Children with Primary Immune Thrombocytopenia. Egyptian Journal of Haematology 2023. [Epub ahead of print]
118. Ebeid FSE, Mokhtar GM, Abdelmaksoud MF, Shnouda SAF, Sayed SM. The Effectiveness of Ambition Development Program among Children with Acute Lymphoblastic Leukemia. Accepted for publication in The Egyptian Journal of Haematology on 4 Sep 2023. [Epub ahead of print]
